Fig. 2.

Survival duration of the collected de novo AL-HGBL-MBR cases. a Kaplan-Meier survival distributions of 46 cases. Median survival was five months [95% CI 3–7]. b There was no significant difference in the survival durations between older (≥60 years, n = 25) and younger (<60 years, n = 21) patients (median five [95% CI 3–7] vs. six [95% CI 3–9] months, log-rank test, P = 0.198). c Among 44 cases receiving chemotherapy, the survival in patients treated with rituximab (n = 16) was significantly improved, compared with in patients treated without rituximab (n = 28) (median seven [95% CI 3.5-NA] vs. five [95% CI 3–7] months, log-rank test, P = 0.0294). All P values were two-tailed, and P < 0.05 was considered significant